The hydrophilic bile acid ursodeoxycholic acid has recently been shown to reduce
The bile acid ursodeoxycholic acid occurs naturally in small quantities in human bile (<4% of total bile acids). It is formed by 7-,B epimerisation of the primary bile acid chenodeoxycholic acid through the action of intestinal bacteria. It was first isolated earlier this century from the bile of the Chinese black bear, after which species it was named.' Nearly 40 years ago it was manufactured synthetically in Japan, finding use as a treatment for a wide range of liver diseases. Its popularity stemmed not from rigorous scientific study but from a longstanding tradition of the beneficial properties of black bear bile ('Yutan').' More general interest in the compound was aroused 15 years ago when Japanese investigators reported that ursodeoxycholic acid desaturated bile and dissolved cholesterol gall stones. 2 Leuschner and colleagues were the first to report in an English language journal improvement in liver function tests in patients with liver disease.3 As a chance finding, they observed this improvement in a group of patients with chronic liver disease who were receiving ursodeoxycholic acid to dissolve gall stones. This report stimulated interest in the compound as a treatment for a variety of adult and childhood liver disorders, principally those resulting in cholestasis. The result has been a large number of uncontrolled studies, with the preliminary results of controlled studies now beginning to emerge. This review attempts to place in perspective the role of ursodeoxycholic acid in the treatment of liver disease, with discussion of recent data on its mechanism of action. The 56 The second mechanism, possibly a consequence of the first, .is the retention of hydrophobic endogenous bile acids, including chenodeoxycholic, deoxycholic, and lithocholic acids (see Figure) . These 17 21 The maximum reduction in serum biochemical parameters occurs during the first year of treatment. 16 Hadziyannis and colleagues found that, particularly in patients with stages III and IV of the disease, biochemical and symptomatic deterioration occurred during the second year of treatment. ' The results of large multicentre trials of ursodeoxycholic acid currently in progress will be needed before it is known whether liver histology is improved in patients with primary biliary cirrhosis. Longer term controlled studies will then be necessary to determine if the short term effect is maintained and whether there is an effect on prognosis. These could be mounted once the current trials are completed (assuming a beneficial effect in the medium term is confirmed). It seems reasonable to surmise that a beneficial effect on prognosis would be to prolong the asymptomatic phase of the disease rather than arrest it, slowing progress towards cirrhosis and liver failure. Indeed, recent work shows that, contrary to previously held beliefs, asymptomatic primary biliary cirrhosis is associated with a reduction in life expectancy.59 Because of this, and being mindful of the long experience of the use of ursodeoxycholic acid in gall stone disease suggesting a lack of adverse effects, early treatment might be advocated to achieve the maximum impact. This would also be the period in which any effect on reduction of immunological injury would be most productive. Therefore it should not be unethical to mount longer term studies in asymptomatic patients. Given the different mechanisms which are thought to produce liver injury in primary biliary cirrhosis, it may also be appropriate to consider combining a drug specifically targeted at the immune system with ursodeoxycholic acid in future trials.
Other cholestatic liver diseases, in particular those associated with primary sclerosing cholangitis and cystic fibrosis, are at present virtually untreatable, so large multicentre controlled trials are urgently needed. Since these diseases share a common feature with primary biliary cirrhosis, namely accumulation of toxic hydrophobic bile acids, it is not unreasonable to hope that ursodeoxycholic acid treatment will be beneficial. It 
